Hikma Pharmaceuticals (LON:HIK) had its price target raised by Barclays from GBX 1,800 ($23.52) to GBX 1,900 ($24.83) in a research report released on Tuesday, ThisIsMoney.Co.Uk reports. They currently have an equal weight rating on the stock.

HIK has been the subject of a number of other reports. JPMorgan Chase & Co. restated a neutral rating and issued a GBX 1,700 ($22.21) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, June 18th. Peel Hunt restated a hold rating and issued a GBX 2,050 ($26.79) price objective (up from GBX 1,870 ($24.43)) on shares of Hikma Pharmaceuticals in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. Hikma Pharmaceuticals currently has a consensus rating of Hold and an average target price of GBX 1,848.57 ($24.15).

Shares of LON HIK opened at GBX 2,043 ($26.70) on Tuesday. Hikma Pharmaceuticals has a twelve month low of GBX 1,491.50 ($19.49) and a twelve month high of GBX 2,089 ($27.30). The firm has a market cap of $4.94 billion and a P/E ratio of 13.73. The company has a 50 day moving average of GBX 1,863.16 and a 200 day moving average of GBX 1,746.92. The company has a quick ratio of 0.78, a current ratio of 1.28 and a debt-to-equity ratio of 37.69.

The business also recently announced a dividend, which will be paid on Monday, September 23rd. Shareholders of record on Thursday, August 22nd will be given a $0.14 dividend. This represents a yield of 0.59%. The ex-dividend date is Thursday, August 22nd. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is presently 0.19%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.

See Also: Return on Equity (ROE)

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.